Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Catabasis Pharma (CATB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,559
  • Shares Outstanding, K 7,142
  • Annual Sales, $ 500 K
  • Annual Income, $ -27,360 K
  • 36-Month Beta 1.75
  • Price/Sales 65.93
  • Price/Cash Flow N/A
  • Price/Book 0.78

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.95
  • Number of Estimates 2
  • High Estimate -0.90
  • Low Estimate -1.00
  • Prior Year -2.40
  • Growth Rate Est. (year over year) +60.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.02 +6.47%
on 02/15/19
6.90 -37.97%
on 01/17/19
-1.22 (-22.18%)
since 01/15/19
3-Month
3.60 +18.89%
on 12/27/18
6.90 -37.97%
on 01/17/19
-2.14 (-33.33%)
since 11/15/18
52-Week
3.60 +18.89%
on 12/27/18
21.80 -80.37%
on 03/16/18
-9.62 (-69.21%)
since 02/15/18

Most Recent Stories

More News
Catabasis Pharmaceuticals Appoints Joanne T. Beck to its Board of Directors

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the appointment of Joanne T. Beck, Ph.D., to its Board of Directors. Dr....

CATB : 4.28 (-3.39%)
Catabasis Pharmaceuticals Announces Pricing of $20 Million Underwritten Public Offering

Catabasis Pharmaceuticals, Inc. ("Catabasis," the "Company," "we," "our," or "us") (NASDAQ: CATB), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten...

CATB : 4.28 (-3.39%)
Catabasis Pharmaceuticals Announces Proposed Underwritten Public Offering

Catabasis Pharmaceuticals, Inc. ("Catabasis," the "Company," "we," "our," or "us") (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it intends to offer...

CATB : 4.28 (-3.39%)
New Research: Key Drivers of Growth for Tiffany, CarMax, Cars, RPC, Cleveland-Cliffs, and Catabasis Pharmaceuticals -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Tiffany & Co. (NYSE:TIF),...

TIF : 90.83 (+0.55%)
CARS : 25.34 (-1.63%)
RES : 10.58 (+0.09%)
CATB : 4.28 (-3.39%)
KMX : 62.06 (+1.47%)
CLF : 11.29 (+0.44%)
Catabasis Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

Catabasis Pharmaceuticals, Inc. (CATB) has been struggling lately, but the selling pressure may be coming to an end soon.

CATB : 4.28 (-3.39%)
Is Catabasis Pharmaceuticals (CATB) Outperforming Other Medical Stocks This Year?

Is (CATB) Outperforming Other Medical Stocks This Year?

CATB : 4.28 (-3.39%)
Agenus (AGEN) Surges: Stock Moves 9.4% Higher

Agenus (AGEN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

AGEN : 3.61 (+1.98%)
CATB : 4.28 (-3.39%)
Catabasis Pharmaceuticals Appoints Gregg Lapointe to its Board of Directors

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the appointment of Gregg Lapointe to its Board of Directors. Mr. Lapointe...

CATB : 4.28 (-3.39%)
Catabasis Pharmaceuticals Phase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular Dystrophy Progress Update and Additional Trial Sites Open for Enrollment

-- Global Start-Up Activities Ongoing with Clinical Trial Application Approvals Received in Canada and Multiple European Countries --

CATB : 4.28 (-3.39%)
Catabasis Pharmaceuticals Announces Reverse Stock Split

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it will effect a one-for-ten reverse stock split of its common stock...

CATB : 4.28 (-3.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade CATB with:

Business Summary

Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054...

See More

Key Turning Points

2nd Resistance Point 4.77
1st Resistance Point 4.53
Last Price 4.28
1st Support Level 4.03
2nd Support Level 3.77

See More

52-Week High 21.80
Fibonacci 61.8% 14.85
Fibonacci 50% 12.70
Fibonacci 38.2% 10.55
Last Price 4.28
52-Week Low 3.60

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar